ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Venclexta already has a fairly broad label in the relapsed/refractory CLL population, but the previously-untreated patient group represents another 20,000 or so potential patients in the US ...

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a ...

Grail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test ...